S-adenosylmethionine (SAMe) as treatment for depression: a systematic review

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major depression is a prevalent mood disorder with significant public health implications.
• Current treatments for depression have limitations, necessitating exploration of novel therapeutic agents.
• S-adenadenosylmethionine (SAMe) is a naturally occurring compound involved in various biochemical processes, including neurotransmitter synthesis.

Purpose of the Study:

• To systematically review and assess the available evidence on S-adenosylmethionine (SAMe) supplementation for the treatment of depression.
• To evaluate the efficacy and safety of SAMe as a therapeutic intervention for major depressive disorder.

Main Methods:

• Comprehensive literature search of multiple databases (Medline, Psychinfo, AMED, Cochrane) up to September 2001.
• Inclusion of various study designs including randomized controlled trials, intervention studies, and reviews.
• Independent evaluation of study quality and extraction of relevant data by two abstractors.

Main Results:

• Eleven articles met inclusion criteria, encompassing five intervention trials, two RCTs, two reviews, one controlled clinical trial, and one meta-analysis.
• Analysis of the Hamilton Rating Scale for Depression showed a favorable and significant between-group effect favoring SAMe.
• Evidence suggests a positive impact of SAMe on depressive symptoms.

Conclusions:

• SAMe supplementation appears to have a role in the short-term treatment of major depression in adults.
• Further research is warranted to elucidate the mechanism of action, bioavailability, and optimal use of oral SAMe.
• Additional studies investigating SAMe as both an independent and adjuvant therapy for adult depression are indicated.